the A and B mutated Hoxb4 expressing progenitors had a significantly reduced recovery to the PBL recovery in comparison to Hoxb4(WT) (p < 0.05). Together, these studies suggest that different intracellular levels of Hoxb4 protein are affecting different types of hematopoietic progenitors. Early ex vivo expansion of clonogenic progenitors was achieved with mutated Hoxb4 proteins without impairing HSC long-term reconstituting ability. Thus, mutated Hoxb4 could represent a useful tool to accelerate engraftment after HSC transplantation.

**SUPPORTIVE CARE**

**198**

**THE USE OF RECOMBINANT HUMAN ERTHROPOIETIN (RHEUPO) AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (ASCT) REDUCES RED BLOOD CELL (RBC) TRANSFUSION REQUIREMENTS**

Ladaique, P.1, El Cheikh, J.1, Faucher, C.1, Forst, S.1, Mohty, M.1, Ladaigque, P.1, Lemarie, C.1, Charbonnier, A.1, Coo, D.1, Sciano, J.M.1, Vernet, F.1, Blaise, D.1 1Institut Paul-Calmettes, Marseille, France.

We previously reported that hemoglobin (Hb) recovery was hastened after RIC ASCT as compared with ASCT after myeloablative conditioning (Transfusion, 44:301-8, 2004). In this setting pretransplant Hb level becomes the major predictive factor for early Hb recovery posttransplant and RBC transfusion (RBCT) requirements. We subsequently reported the efficacy of early rHuEpo administration after RIC ASCT to hasten Hb reconstitution (BMT, 36:901-6, 2005). Here we further confirm that early post-transplant rHuEpo after RIC reduces also RBC requirements. 40 pts surviving at least 60 days were analyzed. Pts characteristics were as follow: age: 50 (27-64); M/F: 28/12; with myeloid (4), lymphoid (29) or solid (7) malignancies. They received a RIC (Fludarabin (150 mg/m²), Busulfan (8mg/kg) and thymoglobulin (2.5 

**200**

**COST ANALYSIS OF ALLOGENIC PERIPHERAL BLOOD TRANSPLANTATION: IMPACT OF DEGREE OF MUCOSITIS AND USAGE OF PALIFERMIN**

Doley, M.J.1, Schwarzler, A.1, Poole, S.G.1, Radakubrunia, M.1, Farag, S.1, Neville, M.2, Lee, J.2 1The Alfred, Melbourne, Victoria, Australia; 2Prestium Pty Ltd, Sydney, New South Wales, Australia.

**Background:** Oral mucositis is associated with increased clinical events and healthcare resource utilization in patients receiving hematologic stem cell transplantation (HSCT) following myeloablative therapy. Palifermin is a recombinant human keratinocyte growth factor approved to prevent severe oral mucositis. The impact of palifermin in the allogenic peripheral blood (PBSTC) and the costs associated has not been quantified.

**Aim:** To assess the clinical and economic impact of palifermin use in allogenic HSCT patients.

**Method:** This was a retrospective review of 21 patients undergoing allogenic HSCT following myeloablative chemotherapy at The Alfred from June 2004-October 2005; versus allogenic HSCT patients receiving palifermin from October 2005-July 2006. We calculated descriptive statistics on duration and grade of oral mucositis; hospital length of stay (LOS), antibiotic use; antifungal use; and total parenteral nutrition (TPN). Costs were determined through data extracts from the hospital’s clinical costing system and through retrospective medical record review.
Results: There were twenty-one patients in the historic control group. The total cost of the hospital admissions was $AUD1,771,448 (average $AUD84,354, range $AUD28,856-276,989). Total pharmaceutical costs for all 21 patients was $AUD 798,583, representing 45% of total costs.

Twenty (95%) patients in the historical group experienced mucositis with 48% having grade 3 or 4. All five patients who received palifermin experienced mucositis but no patients had grade 3 or 4. The average number of TPN days was 8.3 days (median 9.5 days) in the control group compared to 12.2 days (median 9.0 days) in palifermin recipients. Patients that received palifermin had a mean LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days (median 35) for the control group.

Conclusion: Palifermin usage was associated with a decreased incidence and severity of oral mucositis with a reduction in LOS, antibiotic and antifungal costs. Further validation of these results is required in a larger cohort of patients.

Impact of Degree of Mucositis and Usage of Palifermin

<table>
<thead>
<tr>
<th></th>
<th>Historical Control (n=21)</th>
<th>Palifermin treated group (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucositis any Grade</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Mucositis Grade 3 or 4</td>
<td>3.3</td>
<td>0</td>
</tr>
<tr>
<td>Mucositis Grade 3 or 4 - pts (5)</td>
<td>11 ($2.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>TPN usage - mean days duration</td>
<td>8</td>
<td>12.2</td>
</tr>
<tr>
<td>TPN usage - median days duration</td>
<td>9.5</td>
<td>9.0</td>
</tr>
<tr>
<td>Duration of hospitalisation - mean days</td>
<td>36.5</td>
<td>34.4</td>
</tr>
<tr>
<td>Duration of hospitalisation - median days</td>
<td>35.0</td>
<td>25.0</td>
</tr>
<tr>
<td>Antifungal usage - mean $AUD</td>
<td>$15,728</td>
<td>$12,854</td>
</tr>
<tr>
<td>Antifungal usage - median $AUD</td>
<td>$10,720</td>
<td>$2,389</td>
</tr>
<tr>
<td>Total cost antibiotics, antifungals, TPN - mean $AUD</td>
<td>$20,929</td>
<td>$18,811</td>
</tr>
<tr>
<td>Total cost antibiotics, antifungals, TPN - median $AUD</td>
<td>$15,553</td>
<td>$5,605</td>
</tr>
</tbody>
</table>

Method: The costs associated with patients undergoing allogeneic PBSCT and TBI following high dose chemotherapy were quantified. Consecutive patients who received palifermin (Oct 05-July 06) and a control group (June 04-Oct 05) that had not were included. Costs were determined through data extracts from the hospital’s clinical costing system and through retrospective medical record review. Incidence, duration and grade of mucositis, length of hospital stay (LOS), anti-infective use and requirements for total parenteral nutrition (TPN) were quantified.

Results: There were eleven patients in the historic control group and ten (91%) experienced mucositis. Five patients were evaluated in the palifermin group and all experience mucositis. The average number of days of oral mucositis was 8.0 days in the palifermin group compared to 17 days in the control group. None of the palifermin treated patients experienced grade 3 or 4 mucositis compared to 73% in the control group who had an average duration of Grade 3-4 mucositis of 8 days (median 6 days). Patients that received palifermin had a mean LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days (median 28) for the control group. The average number of TPN days with palifermin recipients was 12.2 days (median 9.0 days) compared to 8 days (median 9 days) in the control group. For one patient who received palifermin, TPN usage (37 days) was indicated for severe nausea rather than mucositis. The total costs of antibiotics, antifungals and TPN during the period of hospitalisation was on average $AUD18,811 (median $AUD5,606) for those patients who received palifermin compared to $AUD18,324 (median $AUD8,856) for those that did not.

Conclusion: Palifermin usage was associated with a substantial decreased incidence and severity of oral mucositis with a reduction in LOS in patients who received TBI with allogenic PBSCT. Further validation of these results is required in a larger cohort of patients.

201 IMPACT OF PALIFERMIN ON HOSPITAL RESOURCE CONSUMPTION ASSOCIATED WITH ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION AND TOTAL BODY IRRADIATION

Doddy, M.J.1, Sebauer, A.1, Radhakrishnan, M.1, Poole, S.G.1, Neville, M.A.1, Jennifer, L.1, Farag, S.1, ‘The Alfred, Melbourne, Victoria, Australia; ’Pretium Pty Ltd, Sydney, New South Wales, Australia.

Background: The impact of oral mucositis associated with autologous stem cell transplantation (SCT) following high dose chemotherapy and radiotherapy has been evaluated in the clinical trial setting to assess the effects of palifermin. The impact of palifermin in the allogeneic peripheral blood (PBSCT) and TBI and the costs associated has not been quantified.

Aim: To perform an analysis of the costs associated with allogeneic PBSCT in patients who received TBI and assess the impact of oral mucositis and palifermin.

Method: The costs associated with patients undergoing allogenic PBSCT and TBI following high dose chemotherapy were quantified. Consecutive patients who received palifermin (Oct 05-July 06) and a control group (June 04-Oct 05) that had not were included. Costs were determined through data extracts from the hospital’s clinical costing system and through retrospective medical record review. Incidence, duration and grade of mucositis, length of hospital stay (LOS), anti-infective use and requirements for total parenteral nutrition (TPN) were quantified.

Results: There were eleven patients in the historic control group and ten (91%) experienced mucositis. Five patients were evaluated in the palifermin group and all experience mucositis. The average number of days of oral mucositis was 8.0 days in the palifermin group compared to 17 days in the control group. None of the palifermin treated patients experienced grade 3 or 4 mucositis compared to 73% in the control group who had an average duration of Grade 3-4 mucositis of 8 days (median 6 days). Patients that received palifermin had a mean LOS of 34.4 days (median 25.0 days) compared to mean of 36.5 days (median 28) for the control group. The average number of TPN days with palifermin recipients was 12.2 days (median 9.0 days) compared to 8 days (median 9 days) in the control group. For one patient who received palifermin, TPN usage (37 days) was indicated for severe nausea rather than mucositis. The total costs of antibiotics, antifungals and TPN during the period of hospitalisation was on average $AUD18,811 (median $AUD5,606) for those patients who received palifermin compared to $AUD18,324 (median $AUD8,856) for those that did not.

Conclusion: Palifermin usage was associated with a substantial decreased incidence and severity of oral mucositis with a reduction in LOS in patients who received TBI with allogenic PBSCT. Further validation of these results is required in a larger cohort of patients.

202 ROLE OF TRANSFUSION IN STEM CELL TRANSPLANTATION: A FREE-DOM-FROM-TRANSFUSION (FFT), COST AND SURVIVAL ANALYSIS

Ganguly, S.1, Bradley, J.P.1, Skineka, B.S.1, Dreiz, C.L.1, Deanna-Limayo, D.1, Bodenstein, D.B.1, Patel, J.S.1 (University of Kansas Medical Center, Kansas City, KS).

Introduction: Transfusion of blood products is often an integral part of stem cell transplantation (SCT). Little literature exists to define the impact of transfusion on the outcome of SCT.

Methods: In an attempt to evaluate the need and volume of transfusion in patients undergoing SCT in our institution, we retrospectively evaluated the records of all patients who received SCT from 1995 till 2000.

Results: Out of 210 patients, 154 patients received autologous SCT and 56 patients received allogeneic SCT between 1995 and 2000. Non-Hodgkin’s lymphoma (53%) and leukemia (73%) were the most frequent indications for autologous and allogeneic SCT respectively. Peripheral blood stem cell (PBSCT) was used in all but one patient undergoing autologous SCT. Fifty patients received PBSCT and 16 patients received bone marrow as the source of stem cells during allogeneic SCT. One hundred thirty eight (90%) out of 154 patients undergoing autologous SCT and 24 (43%) out of 56 patients with allogeneic SCT exhibited total hematopoietic engraftment and freedom from transfusion (FFT). Time to achieve FFT (mean length; range) for RBC units for autologous SCT (12; 0-183) was significantly shorter compared with allogeneic SCT (16.5; 0-373). Number of RBC units (median; range) transfused were less in patients undergoing autologous SCT (4; 0-26) compared with patients undergoing allogeneic SCT (6.5; 0-54). The median cost of transfusion was significantly higher in patients undergoing allo-geneic SCT (6.5; 0-54). The number of transfused RBC and platelet units negatively correlated with overall survival (median duration of follow-up 1.3 years) in patients with autologous SCT, but not in patients with allogeneic SCT. This significance remained valid in both continuous regression analysis by Cox and dichotomous analysis (above and below median number of transfused units) by Kaplan-Meier.